BioSpace News Archive

CeloNova BioSciences, Inc. (CeloNova), a global medical device company that offers a family of innovative products based upon its proprietary Polyzene™-F nanocoating technology, today announced its flagship COBRA PzF NanoCoated Coronary Stent (NCS) achieved exceptional long-term ischemic safety of 0% definite and probable stent thrombosis (ST) and low ischemia-driven target lesion revascularization

Vivera Pharmaceuticals, Inc., an innovative, science-driven pharmaceutical company, has named Farah Al Qaissieh to the Ambassador Board of its Neurosciences Division

Neutra Corp. is moving to the second step in the process of gaining acceptance as a vendor at one of three regional big box store chains.

Compass Therapeutics, Inc. (“Compass”; OTCQB: CMPX), a clinical-stage biotechnology company developing proprietary antibody therapeutics to treat cancer, and TRIGR Therapeutics, Inc. (“TRIGR”), a private biotechnology oncology company, today announced that the companies have entered into a definitive merger agreement, under which Compass, through a subsidiary, will acquire TRIGR,

Fuse Medical, Inc. (OTCPINK: FZMD) (“Fuse” or the “Company”) an emerging manufacturer and distributor of innovative medical devices for the orthopedic and spine marketplace, announced that it has filed its quarterly report on Form 10-Q for the quarter ended March 31, 2021 with the Securities and Exchange Commission (“SEC”) on Wednesday, May 12, 2021.

Nanotechnology firm, IdentifySensors Biologics, in partnership with Purdue University, announced that it has completed development of an all-new diagnostic technology platform that detects numerous pathogens, including COVID-19, using electronic nanosensors.

Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced financial results for the first quarter ended March 31, 2021 and provided a corporate update.

Inupadenant updated monotherapy clinical data and evidence of association of A2A receptor expression with anti-tumor activity to be presented at the ASCO 2021 Annual Meeting in June

Nkarta, Inc., a biopharmaceutical company developing engineered natural killer cell therapies to treat cancer, reported financial results for the first quarter ended March 31, 2021.

Marrone Bio Innovations, Inc. has provided its financial results for the first quarter ended March 31, 2021.